UK Markets close in 5 hrs 4 mins
  • FTSE 100

    7,139.78
    +10.57 (+0.15%)
     
  • FTSE 250

    22,769.14
    +84.30 (+0.37%)
     
  • AIM

    1,191.51
    +2.77 (+0.23%)
     
  • GBP/EUR

    1.1728
    -0.0038 (-0.33%)
     
  • GBP/USD

    1.3268
    -0.0034 (-0.2561%)
     
  • BTC-GBP

    42,936.42
    +365.66 (+0.86%)
     
  • CMC Crypto 200

    1,453.05
    +14.17 (+0.98%)
     
  • S&P 500

    4,577.10
    +64.06 (+1.42%)
     
  • DOW

    34,639.79
    +617.75 (+1.82%)
     
  • CRUDE OIL

    68.09
    +1.59 (+2.39%)
     
  • GOLD FUTURES

    1,773.10
    +10.40 (+0.59%)
     
  • NIKKEI 225

    28,029.57
    +276.20 (+1.00%)
     
  • HANG SENG

    23,766.69
    -22.24 (-0.09%)
     
  • DAX

    15,254.46
    -8.65 (-0.06%)
     
  • CAC 40

    6,787.82
    -7.93 (-0.12%)
     
Markets:

European stock markets push higher as Omicron strain concerns ease

AURELIUS Equity Opportunities co-invests in the acquisition of McKesson UK

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

AURELIUS Equity Opportunities SE & Co. KGaA / Key word(s): Takeover
AURELIUS Equity Opportunities co-invests in the acquisition of McKesson UK

01-Nov-2021 / 13:02 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Inside Information according to Article 17 MAR

AURELIUS Equity Opportunities co-invests in the acquisition of McKesson UK

Grünwald, November 1, 2021 - AURELIUS Elephant Limited, a subsidiary of AURELIUS Equity Opportunities SE & Co. KGaA ("AEO"; ISIN: DE000A0JK2A8) and AURELIUS European Opportunities IV, S.C.A. ("AURELIUS European Opportunities Fund IV"), today signed a binding agreement to acquire the UK business activities of McKesson ("McKesson UK") from McKesson Corporation, Irving, Texas, in a corporate carve-out deal.

The deal with an enterprise value of GBP 477 million will be acquired through the recently launched co-investment structure with AURELIUS European Opportunities Fund IV controlling a 70% stake and AURELIUS Equity Opportunities SE & Co. KGaA (ISIN: DE000A0JK2A8) controlling 30%. The transaction is expected to close in Q1 2022, subject to customary closing conditions, including receipt of required regulatory approvals.

The McKesson UK business has an established position in the healthcare sector, comprising Lloyds Pharmacy as well as wholesale pharmaceuticals distributor, AAH Pharmaceuticals and generated over GBP 5 billion in revenues and an EBITDA in the high double-digit millions in 2020.

McKesson UK operates four divisions: retail, digital, homecare and wholesale. The business has over 18,000 employees, including pharmacists, nurses, logistics operatives as well as store, warehouse and administration personnel.

To find out more, visit www.aureliusinvest.com
 

CONTACT
AURELIUS Equity Opportunities SE & Co. KGaA
Investor Relations & Corporate Communications
Phone: +49 (89) 544799 - 0
Fax: +49 (89) 544799 - 55
E-mail: investor@aureliusinvest.de




 

01-Nov-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

AURELIUS Equity Opportunities SE & Co. KGaA

Ludwig-Ganghofer-Straße 6

82031 Grünwald

Germany

Phone:

+49 (0)89 544 799-0

Fax:

+49 (0)89 544 799-55

E-mail:

info@aureliusinvest.de

Internet:

www.aureliusinvest.de

ISIN:

DE000A0JK2A8

WKN:

A0JK2A

Listed:

Regulated Unofficial Market in Berlin, Frankfurt, Hamburg, Munich (m:access), Stuttgart, Tradegate Exchange

EQS News ID:

1245133


 

End of Announcement

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting